Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete or partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
IV cyclophosphamide showed no clear difference in treatment response at 18 months: sustained… compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
IV cyclophosphamide showed no clear difference in treatment response at 18 months: CKD compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
IV cyclophosphamide showed no clear difference in adverse events: bacterial infections compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).